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Abstract
Toll-like receptors (TLRs) that recognize pathogen associated molecular patterns and chemoattractant receptors (CKRs) that
orchestrate leukocyte migration to infected tissue are two arms of host innate immunity. Although TLR signaling induces
synthesis and secretion of proinflammatory cytokines and chemokines, which recruit leukocytes, many studies have
reported the paradoxical observation that TLR stimulation inhibits leukocyte chemotaxis in vitro and impairs their
recruitment to tissues during sepsis. There is consensus that physical loss of chemokine receptor (CKR) at the RNA or protein
level or receptor usage switching are the mechanisms underlying this effect. We show here that a brief (,15 min)
stimulation with LPS (lipopolysaccharide) at ,0.2 ng/ml inhibited chemotactic response from CCR2, CXCR4 and FPR
receptors in monocytes without downmodulation of receptors. A 3 min LPS pre-treatment abolished the polarized
accumulation of F-actin, integrins and PIP3 (phosphatidylinositol-3,4,5-trisphosphate) in response to chemokines in
monocytes, but not in polymorphonuclear neutrophils (PMNs). If chemoattractants were added before or simultaneously
with LPS, chemotactic polarization was preserved. LPS did not alter the initial G-protein signaling, or endocytosis kinetics of
agonist-occupied chemoattractant receptors (CKRs). The chemotaxis arrest did not result from downmodulation of
receptors or from inordinate increase in adhesion. LPS induced rapid p38 MAPK activation, global redistribution of activated
Rap1 (Ras-proximate-1 or Ras-related protein 1) GTPase and Rap1GEF (guanylate exchange factor) Epac1 (exchange proteins
activated by cyclic AMP) and disruption of intracellular gradient. Co-inhibition of p38 MAPK and Rap1 GTPase reversed the
LPS induced breakdown of chemotaxis suggesting that LPS effect requires the combined function of p38 MAPK and Rap1
GTPase.
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Introduction
Cells of myelomonocytic lineage constitute the first lines of
defense against pathogens. Of these, the short-lived, free-roaming
neutrophils are the primary sentinels that respond to intrinsic and
extrinsic chemical and environmental cues from the inflammatory
foci, and set up robust anti-microbial effector functions. Mono-
cytes and monocyte-derived macrophages subserve other functions
including, but not limited to phagocytosis, antigen presentation,
and initiation of acquired immunity.
Leukocytes are endowed with a diverse family of G-protein
coupled receptors (GPCRs) that sense chemoattractants and
regulate directed cell migration in the immune system [1]. During
chemotaxis, which is governed by spatially restricted integration of
diverse signaling pathways that lead to cell polarity [2], leukocytes
change rapidly from a roughly spherical to a polarized
morphology with distinct leading and trailing edges and F-actin
accumulation at the front [3].
Toll-like receptor (TLR) family members recognize microbial
products to usher in innate immune response and bridge the
innate and acquired immune response to pathogens Of the TLRs,
TLR4 forms hetero- and homo-dimers at the cell surface and is the
sole receptor for lipoplysaccharide (LPS). TLR signaling stimulates
various transcriptional pathways, which prime innate immune
cells against pathogens by facilitating pro-inflammatory cytokine
and chemokine secretion [4].
Both positive and negative effects of TLR ligands on neutrophil
chemotaxis have been documented. Besides being recognized as a
surrogate chemoattractant by neutrophils [5]; LPS treatment
enhanced neutrophil chemotaxis through increased expression
(and secretion) of chemokines and cognate receptors [6]; induction
of MMP-8 cleavage of LIX chemokine to enhance CXCR2
binding [7]; or downregulation of GRK2 and GRK5 (G protein-
coupled receptor kinase 2 or 5) mRNAs thus decreasing CXCR2
desensitization [8]. In contrast, septic neutrophils or control cells
treated with cytokines plus LPS or LTA were impaired for
chemotaxis through enhanced GRK2 and GRK5 expression [9]
or down-modulation of CXCR1/2 [10]. LPS also inhibited
migration towards endogenous chemokines through p38 MAPK
and concomitant inhibition of PI3K (phosphatidylinositol-3-
phosphate kinase) [11].
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30404TLR signaling also downregulates CKRs on monocytes. LPS at
100 ng/ml for 1 h decreased the steady state levels of CCR2 and to
a lesser extent, CCR1 and CCR5 mRNA [12,13] and promoted
tyrosine kinasemediated serineprotease degradationofCCR2 [14];
LPS at 10 mg/ml enhanced chemokine secretion, which downreg-
ulated cognate receptors CCR1 and CCR2 through autocrine
pathway [15]; 20 hr treatment with Pam3CSK4 at 50 ng/ml
induced selective reduction in chemokine receptor transcript levels
[16]; while treatment with LTA at 10 mg/ml for 1 h downregulated
CCR1, 2 and 5 on human monocytes by recruiting the endocytic
machinery of agonist mediated downmodulation [17].
LPS at 1 mg/ml increased adherence of THP-1 monocytes
through PI3-K mediated LFA-1 (leukocyte function-associated
antigen-1 or integrin aLb2) activation [18] or by Rap1 GTPase
regulated Mac-1 (macrophage-1 antigen or integrin aMb2)
activation [19]; or by actin reorganization by phosphorylated
tyrosine kinase, Pyk2 and paxillin [20]. More recently it was shown
that while LPS at 1 mg/ml for 15 min increased integrin activation
and matrix adhesion and a corresponding decrease in TEM under
static conditions, it did not alter monocyte adhesion or migration
under conditions of physiological flow [21].
As extensive and varied as the above observations are, they
represent results of TLR signaling at high ligand inputs over
prolonged periods when the full gamut of TLR signaling is in play.
Here, we have evaluated the effects of short-term (15 min)
treatment of pro-inflammatory leukocytes with limiting amounts
of TLR agonists. We show that LPS (2 ng/ml), induced immediate
cellspreading andchemotactic arrestin primary humanmonocytes,
but not in PMNs and myelomonocytic cell line U-937. Chemotactic
arrest resulted from rapid global induction of PIP3 production,
which primed p38 MAPK and Rap1 signaling. These events led to
symmetric LFA-1 and Mac-1 activation and global F-actin
distribution, both of which combined to increase adhesion and
inhibit chemotaxis. Combined inhibiton of p38 MAPK and Rap1
GTPase restored chemotaxis in LPS treated cells.
Results
LPS and other TLR2/4 ligands induced cell spreading and
inhibited chemotactic polarization and migration of
primary human monocytes
LPS and other TLR ligands caused severe inhibition of
chemotactic potential of monocytes towards CCL2, CXCL12
(Figure 1 A) or fMLF (not shown) in the Trans-well assay. To
determine if this characteristic was limited to some TLR ligands,
we tested monocyte chemotaxis after treatment with TLR4
specific LPS, TLR1/2 heterodimer ligand MALP2 (macrophage-
activating lipopeptide-2), TLR3 targeting poly I:C, TLR2/6
specific tripalmitoylated lipopeptide, Pam3CSK4; TLR5 ligand
flagellin, poly(U) that binds TLR7 or 8, TLR9 ligand CpG ODN
(oligo-deoxynucleotide), lipid A (TLR4) and a NOD2 (nucleotide-
binding oligomerization domain) ligand, muramyl dipeptide.
Chemotactic inhibition was observed only with ligands for TLRs
at the cell surface like LPS, MALP2, Pam3CSK4 and to a less
extent flagellin (Figure 1 A).
Substantial inhibition of monocyte chemotaxis towards CCL2
or CXCL12 was observed with LPS around 0.2 ng/ml (Figure 1
B). A 3–10 min treatment with LPS or MALP2 inhibited
monocyte chemotaxis towards CCL2, CXCL12 or fMLF. While
the inhibitory effect of a 3 min LPS treatment was irreversible, a
longer exposure with MALP2 (10–30 min) was necessary to induce
a recalcitrant state (Figure S1). Preincubation with TLR2 or TLR4
antibodies prevented chemotactic inhibition by cognate TLR
agonists (Figure 1 C).
Within 2 min of addition of 20 nM CCL2 or CXL12,
monocytes displayed polarization and assembly of F-actin
polymers at the leading edge. However, a 15 min LPS
pretreatment abolished this response; instead the cells acquired
flattened morphology with circumferential distribution of F-actin
(Figure 1 D, Control vs. LPS). To evaluate the immediate effects of
TLR agonists, we adopted the cell polarization assay to examine
the time course of chemotactic polarization. LPS, MALP-2 and
Pam3CSK4 induced cell spreading with circumferential F-actin
within 3–10 min (Figure 1 E).
To evaluate the primacy of LPS induced arrest over chemokine
induced polarization, and vice versa, we treated monocytes with LPS
eithersimultaneouslywithorshortlyafterthechemokinestimulation.
As illustrated by Figure 1 F (top row), human monocyte polarized
within 2 min after CCL2 addition, slowly decaying to ground state
by 16 min. Adding LPS at the same time as CCL2 did not impair
this polarization (Figure 1F, bottom row). However, adding LPS
3 min prior to CCL2 inhibited polarization (Figure 1F, middle row).
Preincubation with TLR2 or TLR4 antibodies prevented chemo-
tactic inhibition by cognate TLR agonists (not shown).
Neutrophil polarization or chemotaxis was not inhibited
by short-term LPS treatment
We compared the LPS effect on polarization of PMNs vs.
monocytes towards their respective chemokines, CXCL8 or
CCL2. Persistent F-actin polarity and other cytoskeletal dynamics
in response to chemoattractants depend on polarized PI3K
activation leading to PIP3 accumulation at the leading edge.
LPS treated or untreated PMNs were stimulated with 20 nM
CXCL8 for 2 min, fixed and permeabilized and stained with
fluorescent phalloidin and anti-PIP3 mAb. CXCL8 induced
marked F-actin polarization with PIP3 at the leading edge whether
or not PMNs were treated with LPS (Figure 2 A). However, this
was not the case for LPS treated monocytes, which lost CCL2
induced F-actin and PIP3 polarization at the leading edge.
LPS at 0.02 pg/ml induced a mild inhibition of neutrophil
migration towards CXCL8, but there was no dose (LPS 0.02 pg–
0.2 mg/ml) dependent decrease in chemotaxis (Figure 2 B).
Neutrophils exposed to different TLR ligands at 20 ng/ml or less
for ,20 min were not significantly inhibited for migration towards
fMLF or CXCL8 other than the potent inhibitory effect of MALP-
2 (data not shown). Consistent with a previous report [10], longer
(1–2 h) LPS treatment at .200 ng/ml inhibited neutrohil
chemotaxis significantly (not shown), probably resulting from
down-modulation of chemokine receptor CXCR1/2 [10]. Che-
motaxis of human myelomonocytic cell line U937 towards CCL2
was also not significantly inhibited by LPS treatment over a range
of 2–200 ng/ml (Figure 2 C).
LPS treatment did not alter the steady state levels of
CKRs, their G-protein signaling potential or enhance
endocytosis of agonist occupied receptors
Inhibition of chemotaxis by LPS treatment might reflect
downregulation or degradation of CKRs or their respective
mRNAs. If TLR stimulated cells secreted chemokines, they might
desensitize cognate receptors in an autocrine manner. However,
this was unlikely since pro-inflammatory cyto- and chemokine
secretion occurred only after .2 h treatment with various TLR
ligands including LPS at 100 ng/ml or more (Figure S2 A and B).
Consistent with this observation, there was no loss in the steady-
state levels of many different immune cell receptors under the
limited LPS treatment conditions used here (Figure 3 A).
We inquired whether LPS treatment compromised chemoat-
tractant signaling or accelerated endocytosis of agonist occupied
TLR Signaling on Monocyte Chemotaxis
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e30404receptors. We examined the earliest step(s) in GPCR signaling,
namely Gbc dissociation from the agonist occupied receptor. Gbc
dissociation was measured indirectly by monitoring intracellular
Ca
++ flux from ER stores mediated by IP3 from PIP2 hydrolysis by
Gbc activated PLC-b.2 610
6 monocytes were preloaded with the
fluorescent Ca
++ indicator FURA-2 and then treated with LPS or
not. We compared the agonist dose response profiles of Ca
++ flux
in control and LPS treated cells after sequential stimulation with
CCL2 and CXCL12. LPS treated monocytes did not exhibit any
differences in the kinetics or the magnitude of calcium flux
(Figure 3B), with the exception of one donor whose monocytes
were attenuated by LPS for calcium flux from CXCR4 by 40% at
the lowest (10 nM) CXCL12 concentration.
LPS treatment has been demonstrated to modulate the cell
surface levels of many receptors through facilitated endocytosis by
direct binding [17], enhanced constitutive endocytosis or recruit-
ing alternative endogenous agonist(s). To obtain a quantitative
measure of receptor clearance in the control vs. LPS treated cells,
we compared the dose-response and rate curves of agonist-
mediated receptor internalization from the LPS vs. untreated
monocytes. LPS treatment inhibited the magnitude of CCR2 and
CXCR4 internalization at the higher concentrations of chemo-
kine. As illustrated in Figure S3 B, the EC50 was 3–4 fold higher
and t1/2 values two fold more in LPS treated cells for the two
agonist:receptor combinations.
LPS induced the phosphorylation of p38 MAPK and p44/
42 ERK (extracellular-signal-regulated kinase), but
inhibition of these kinases alone did not reverse
chemotaxis arrest by LPS
Since many downstream signaling events of TLR stimulation
have been attributed to MAPK activation [4], we evaluated the
Figure 1. LPS treated human monocytes displayed flattened morphology and are inhibited for chemotaxis. A) Relative chemotactic
inhibition by different TLR ligands. Primary human monocytes were treated with the indicated TLR ligands exactly as described under Methods and
allowed to migrate towards 20 nM CCL2 or CXCL12 in the Trans-well chamber. Data are plotted as histograms with error bars (n=3; **, p,0.03; ***,
p,0.01). B) LPS dose response of chemotactic inhibition of monocytes. Monocytes (5610
5) were pretreated for 15 min with the various
concentrations of LPS, washed 3 X and placed in the upper wells of 5.0 mm Trans-well and allowed to migrate towards 20 nM CCL2 or CXCL12 in the
bottom wells. Relative fraction (%) of input cells that migrated to the bottom well is plotted in the histogram with error bar (n=3; *, p,0.03, **,
p,0.04). C) Chemotaxis of monocytes towards CCL2, CXCL12 or fMLF after preincubation with TLR2, TLR4 ligands in the presence of TLR2, TLR4
antibodies or isotype IgG control. Relative fraction (%) of migrated cells is plotted in the histogram with error bars. D) LPS pretreatment abolished
chemokine induced F-actin polarizarion. Fresh monocytes on cover slips were treated with or without LPS (2 ng/ml) for 15 min at 37uC prior to 2 min
stimulation with 20 nM CCL2 or CXCL12. Cells were fixed and stained with Alexa-488 conjugated phalloidin and examined by fluorescent microscopy
and interference optics (DIC). E) Time course of morphological change in monocytes induced by various TLR ligands (LPS, 2 ng/ml; MALP-2, 200 ng/
ml; and Pam3CSK4, 50 ng/ml). Cells were fixed and stained for F-actin as above. F) F-actin polarization was preserved in monocytes stimulated with
20 nM CCL2 prior to (top row) or simultaneously (bottom row) with LPS at 2 ng/ml. The middle row shows results with cells pretreated with LPS for
3 min before CCL2. Figures in D, E and F represent three independent experiments using monocytes from different donors.
doi:10.1371/journal.pone.0030404.g001
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PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e30404Figure 2. Differential effects of LPS on neutrophil and monocyte chemotaxis. A) LPS pre-treatment affects the polarization of CCL2 treated
monocytes but not CXCL8 treated neutrophils. Human monocytes and neutrophils were plated on cover slips and treated with or without LPS (2 ng/
ml) for 10 min at 37uC. After washing, cells were treated with CXCL8 (PMNs) or CCL2 (MONOCYTES) at 20 nM at 37uC for 2 min. Cells were then fixed,
permeabilized and stained with Alexa568- phalloidin and FITC mAb against PIP3 and imaged by fluorescence and DIC microscopy. B) LPS did not
significantly inhibit neutrophil chemotaxis. Human neutrophils (1610
6 cells in triplicate) were treated with various concentrations of LPS in 100 ml
RPMI with 5% FBS for 10 min at 37uC. After washing, cells were suspended in 100 ml RPMI with 1% FBS and added to the upper chambers of 5.0 mm
Trans-well (Corning Inc.), with or without 20 nm CXCL8 or fMLF (not shown) in the bottom well, and incubated for 2 h at 37uC. Migrated cells were
collected and counted, as described under Methods. Fraction (%) of migrated input cells are presented in the histograms (with error bars), n=3. C)
LPS treatment at 20 ng/ml induced little or no inhibition of of U937 myelmonocytic cell chemotaxis towards 20 nM CCL2, n=3.
doi:10.1371/journal.pone.0030404.g002
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LPS treatment, using flow cytometry and immunoblotting.
Phosphorylated 44/42 ERK increased significantly after CXCL12
treatment, reaching a maximum at 2 min, then decaying slowly
after 5 min of continuous agonist occupancy (Figure 4 A1). By
comparison, p44/42 ERK reached a maximum after 30 min LPS
treatment, slowly decaying after 30 min (Figure 4 A2 and A3).,
Phosphorylation of p38 MAPK followed the same temporal profile
as that of p44/42K after CXCL12 treatment (Figure 4 B1). p38
MAPK was phosphorylated after 15 min of LPS treatment, and
maintained similar levels of activation up to 100 min after LPS
(Figure 4 B2 and B3). Although p38 MAPK phosphorylation by
immunoblotting was observed consistently only after 15 min LPS
treatment, phosphorylated p38 MAPK immunoreactivity was
detected within 5–10 min by flow cytometry (not shown). Since
the temporal profile of p38K activation corresponded with that of
chemotaxis arrest, we used small molecular weight inhibitors,
PD98059 and SB203580 to block activation of p44/42 ERK and
p38 MAPK respectively and evaluated monocyte adhesion,
chemotactic polarization and migration. Neither kinase inhibitor
significantly reversed LPS mediated inhibition of chemotactic
polarization or migration towards CCL2 as shown later in the
manuscript.
LPS pretreatment prevented the polarized distribution of
activated LFA-1 and Mac-1 in chemokine stimulated
monocytes
Among the integrins, LFA-1 and Mac-1, which share b2
integrin, respectively with aLa n daM subunits play important
roles in immune cell migration. Integrin activation exposes
hidden epitope(s), and antibodies against these epitope(s) are used
as markers of integrin activation Preincubating monocytes with
antibodies against (fully extended conformation) LFA-1 (CD11a)
or Mac-1 (CD11b) partially inhibited their chemotaxis towards
CCL2, CXCL12 or fMLF. However, the blocking antibody L130
against b2 integrin induced an almost complete chemotactic
arrest (Figure S4 A). Monocytes treated for 2 min with 20 nM
CCL2 or CXCL12 localized activated LFA-1 (Figure 5 A, left)
and Mac-1 (Figure 5 A, right) to the leading edge enmeshed
within F-actin fibrils whereas in cells pretreated with LPS for
20 min, activated LFA-1, Mac-1 and F-actin were distributed
globally (Figure 5 A, bottom panels). We inquired whether LPS
induced polarization inhibition could be overcome by higher
chemokine levels. We did polarization assays at lower or higher
chemokine concentrations. With primary monocytes, optimal
polarization was observed after 20 nM CCL2 or CXCL12 for
Figure 3. Short term stimulation of monocytes with TLR2 or TLR4 ligand did not significantly modulate cell surface expression of
selected immune cell receptors and LPS treatment did not alter the G-protein signaling potential (as measured by intracellular Ca
2+
flux) to CXCL12 or CCL2 treatment(s). A) Monocytes were treated with LPS (2 ng/ml) or Pam3CSK4 (50 ng/ml) for 15 min before staining with
fluorescent mAbs against the indicated immune cell receptors. Receptor densities were measured by flow cytometry and the MFVs in stimulated cells
are expressed relative (%) to untreated cells as histograms (with error bars, n=3). B) Agonist dose response of intracellular Ca
2+ flux to sequential
stimulation with CXCL12 and CCL2 in monocytes. C)C a
2+ flux profiles of LPS (2 ng/ml, for 15 min after calcium dye loading) treated (interrupted line)
and untreated monocytes to sequential stimulation with increasing concentrations of CXCL12 and CCL2. Plots represent results using monocytes
from four donors.
doi:10.1371/journal.pone.0030404.g003
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quite modest. 100 nM or higher chemokine levels induced rapid
desensitization and signaling decay. LPS pretreatment for 10–
15 min abolished integrin polarization induced over a 5–50 nM
range of chemokine levels.
Human leukocytes contain a large pool of free b2 integrin,
CD18 [22]. A monoclonal antibody, MEM-148, which recognizes
free form of b2 integrin induces a high-affinity conformation in the
native LFA-1, exposing and binding to its cognate epitope [23].
Mg
++/EDTA or low pH (5.5–6.5) treatment also exposes the same
epitope. Within 15 min of TLR agonist treatment(s), there was a
50% increase in MEM-148 binding, reaching 2.5–3 fold times
basal levels after 2–3 h. Among the different TLR ligands, flagellin
was the least effective in inducing this conformational change,
while ligands for intracellular TLRs (i.e. pI:C, CpG, poly(U) and
muramyl peptide) were ineffectual (Figure S4 B).
MEM-148 also localized to the leading edge of CCL2 or
CXCL12 treated monocytes (Figure 5 B). Whether the polarized
MEM-18 staining reflected free CD18 or CD18 dissociated from
quiescent or activated LFA-1 or Mac-1 heterodimers, LPS blocked
b2 integrin localization at the leading edge of CCL2 or CXCL12
treated cells (Figure 5 B). In contrast, CCL2 or CXCL12
treatments did not induce polarized distribution of b1 integrins,
visualized by staining with N29 and 21C8 mAbs against b1
integrin heterodimers (data not shown).
We evaluated proximity interaction(s) between activated b2
integrin and the LPS receptor, TLR4 by live FRET microscopy.
We measured FRET efficiency on the basis of the increase in the
donor fluorescence upon photobleaching the acceptor fluoro-
phore. There was a significant increase in the FRET efficiency
between Alexa-568 conjugated MEM-148 mAb recognizing
activated b2 integrin (CD18) and Alexa-488 mAb against TLR4
Figure 4. LPS induced phosphorylation of MAPKs. p44/42 ERK (A1–A3) and p38 MAPK (B1–B3) were phosphorylated after CXCL12 (20 nM)
stimulation or LPS (2 ng/ml) treatment. Human monocytes (2610
6 cells for each time point) treated with or without CXCL12 were collected at 1.5, 2,
3 and 5 min. Monocytes (5610
6 for each time point) treated with or without LPS were collected 0, 15, 30, 60 and 100 min. Half of the cells treated
with or without LPS and all the cells treated with or without CXCL12 were extracted with RIPA buffer and proteins were resolved by 4–20% gradient
SDS-PAGE. Phospho-ERK and total ERKs were detected by immunoblotting with phospho-ERK specific mAb, E10 and rabbit antibody against total
ERK (A1 and A2). Reacting with anti phospho-p38 MAPK (T180/Y182) mAb and rabbit antibody against total p38 detected phospho-p38 and total
p38 respectively (B1 and B2). Immunoblots are representative of results with monocytes from 3 donors. The remaining half of the cells treated with
or without were stained with a mixture of Alexa-647 E10 mAb against phospho ERK (T202/Y204) and Alexa-488 28B10 mAb against phospho-p38
MAPK (T180/Y182) and analyzed by flow cytometry. Ratios of MFVs for the respective phosho-MAPKs in LPS treated vs. untreated cells are plotted as
histograms (n=5, * p,0.03, ** p,0.01). The remaining cells were extracted with RIPA buffer and proteins resolved by 4–20% gradient SDS-PAGE.
Phospho-ERK and total ERKs were detected by immunoblotting with phospho-ERK specific mAb, E10 and rabbit antibody against total ERK. Reacting
with anti phospho-p38 MAPK (T180/Y182) mAb and rabbit antibody against total p38 detected phospho-p38 and total p38 respectively (A3 and B3)
Immunoblots are representative of results with monocytes from 5 donors.
doi:10.1371/journal.pone.0030404.g004
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e30404Figure 5. LPS treatment induced global activation of LFA-1 and Mac-1 in human monocytes, which was not reversed by chemokine
stimulation. A) Human monocytes on cover slips were incubated with (LPS) or without (CON) LPS at 2 ng/ml for 15 min at 37uC. Cells were then
washed and treated with CCL2 or CXCL12 (20 nM) for 2 min at 37uC. Cells were fixed, permeablized and stained with phalloidin-568 and murine
mAbs against ß2 integrin activation epitopes in LFA-1 (mAb24, left) or Mac-1 (CBRM1/5, right) followed by Alexa-488 conjugated anti-mouse IgG. B)
Cells treated as described above were stained with phalloidin-568 and mAb MEM148 (followed by Alexa-488 conjugated anti-mouse IgG), which
recognizes ß2 integrin activation epitope, irrespective of the heteromeric context. Individual channels corresponding to phalloidin and integrin
staining and composite 2-color images are shown along with DIC images. C) Acceptor photobleaching FRET assay of proximity interaction between
TLR4 and integrins. Human monocytes on cover slips treated with or without LPS (2 ng/ml) for 15 min were fixed and stained with biotin conjugated
anti-TLR4 HTA-125 mAb (TLR4) and MEM148 mAb against a b2-integrin activation epitope (CD18) or CBRM1/5 mAb against activated Mac-1 (CD11b),
followed by staining with Alexa-488 steptavidin and Alexa-568 goat anti-mouse IgG. FRET was performed in a Leica TCS SP5 confocal microscope.
Photo-bleaching was performed with high-intensity laser scanning at 514 nm at 100% power output in defined ROIs (regions of interest). Pre-
bleaching and post-bleaching images were acquired, and the average fluorescence intensity of both donor (Alexa-488) and acceptors (Alexa-568) in
the bleached ROIs were measured using the proprietary Leica acceptor photobleaching program. Ef=(I post2Ipre)/Ipre calculated FRET efficiency (Ef),
where I corresponds to average intensity of donor (Alexa-488). FRET values averaged from ,6 ROIs in each of the 6–10 cells from each of 3 separate
experiments with different donor cells are plotted in the graph with the mean and standard error drawn as box and whiskers (n=3, *** p,0.01).
doi:10.1371/journal.pone.0030404.g005
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between these two proteins. Interaction between activated Mac-1
heterodimer, visualized by CBRM1/5 mAb (CD11b) and TLR4
was not altered by LPS treatment (Figure 5 C). Collectively, these
findings suggested that b2 integrin is activated globally at or very
close to activated TLR4 sites.
Global integrin activation would be expected to increase cllular
adhesion to the substratum and thus counter polarizing chemo-
tactic forces [18,21]. To address this, we performed a HUVEC
(human umbilical vein endothelial cells) cell adhesion assay. We
treated monocytes with LPS for 3, 10, 20, 30, 60 min, or 2 h.
Alternatively cells were treated with LPS for 30 min, followed by a
wash and incubation in LPS free medium for 3, 10, or 120 min.
Monocytes were loaded with Calcein A and allowed to adhere to
HUVEC monolayer for 30 min. Unbound cells were washed
before analysis using Flexstation photometer. As shown in Figure
S4 C, increase in the adhesive potential of LPS treated monocytes
was inconsistent until after 120 min treatment. However, if the
monocytes were rested for 10 min after 30 min LPS treatment
resulted in more consistent increase in monocyte adhesion (Figure
S4 C). Under our LPS treatment conditions, only the inside-out
signaling that leads to partial (and reversible) integrin activation
may be operative and may not be sufficient to sustain strong
adhesions. In contrast, leukocyte adhesion to inflamed vascular
endothelium with chemokines immobilized on the cell surface
GAGs (glycoso-aminoglycan) [24] or to LPS treated HUVECs
over-expressing ICAM-1 (inter-cellular adhesion molecule) and
VCAM-1 (vascular cellular adhesion molecule) [21,25,26] are
driven by bidirectional signaling that induces fully extended
integrin conformations with high-affinity and increased avidity.
The inconsistent increase in the adhesion of LPS treated
monocytes to untreated HUVECs that we observed may not be
sufficient to arrest chemotaxis in the first 15 min of LPS treatment.
Rap1 is markedly activated and distributed globally in
LPS treated monocytes
Integrin activation by chemoattractants and inflammatory
mediators is mediated by inside out signaling through the small
GTPase, Rap1 [19,27]. Rap1 was activated within 2 min with
CCL2 or CXCL12 stimulation (Figure 6 A, lanes 2–3) or after
15 min treatment with LPS alone (Figure 6 A, lane 4), but CCL2 or
CXCL12 treatments following LPS did not further enhance Rap1
activation(Figure 6 A,lanes5–6).Rap-1 levels werenotsignificantly
altered during a 15 min incubation with increasing amounts (2–
100 ng/ml) of LPS (Figure 6 B). We then examined the sub-cellular
distribution of activated Rap1 by reacting with Ral GDS-RBD (Ral
guanine nucleotide dissociation stimulator Ras binding domain)
GST (glutathione S-transferase) fusion protein followed by FITC-
conjugated anti-GST antibody. There was significant sequestration
of activated Rap1 at the leading edge of cells polarized by CCL2
(Figure 6 C). In cells pretreated with LPS for 15 min, activated
Rap1wasgloballydistributed attheplasmamembrane (Figure6C).
Total Rap1 was distributed all along the peripheral membranes in
CCL2 treated cells and in all membranes and focal adhesions in the
LPS treated cells (Figure S5 A).
Five different GEFs, namely CalDAG (Ca
++ and diacyl-
glycerol), PDZ GEF1, PDZ GEF2, Epac1 and C3G [28] activate
Rap1 under different conditions and in various cell types. Among
these GEFs, we found that Epac1 exhibited leading-edge co-
localization with F-actin polymers in monocytes polarized by
chemoattractant treatment(s); LPS pretreatment induced global
recruitment of Epac1 (Figure 6 D).
Since both the release of Epac1 from auto-inhibition and its
recruitment to plasma membrane is critically dependent on cAMP
(cyclic AMP adenosine (39-59) cyclic monophosphate) [29], we
inquired whether LPS induced Rap-1 activation followed this
pathway. While LPS treatment enhanced cAMP synthesis slightly,
this occurred only after 30 min (data not shown). We therefore
inquired whether LPS effects could be simulated by treatment with
thecAMPanalog,8-(4-chloro-phenylthio)-2-O-methyladenosine-3,5-
cyclic monophosphate (8CPT-2Me-cAMP) that specifically targets
Epac and not PKA [30] and has been shown to induce integrin
activation in U937 cells [31]. While 8CPT-2Me-cAMP induced
monocyte cell spreading (Fig S5 B) and global Epac1 recruitment, it
did not inhibit chemotaxis in primary monocytes (data not shown).
Simultaneous inhibition of p38 MAPK and Rap1 reversed
the LPS induced chemotaxis arrest
Rap1 independent pathways may also activate integrins [32].
However since LPS induced marked Rap1 activation, we inquired
whether knocking down membrane recruitment and activation of
Rap by a specific geranyl transferase inhibitor, GGTI-298 would
reverse the chemotaxis arrest by LPS. While GGTI-298 drastically
reduced LPS mediated Rap1 activation (Figure 7 C), it did not
reverse the cell spreading or the loss of F-actin polarization or
trans-well chemotaxis in response to CCL2 in LPS treated cells
(Figure 7 A and B).
LPS-induced cell spreading probably reflects unpolarized b2-
integrin activation. A linear pathway starting with TLR4/MD1
MyD88 (myeloid differentiation primary response gene 88), IRAK
(interleukin-1 receptor-associated kinase), p38 and Rap1 regulates
LPS induced b2-integrin activation [19]. Although both MAPK
(Fig. 4 A and B) and Rap1 (Figure 6 A) were activated upon LPS
simulation, inhibiting either MAPK or Rap1 alone did not reverse
the chemotaxis arrest in LPS treated cells (Figure 7 A and B). LPS
mediated cell spreading and chemotaxis arrest was reversed only
when both Rap1 and p38 MAPK were inhibited with a
combination of GGTI-298 and SB203580. In contrast, co-
inhibition of Rap1 and ERK (PD98059) was not effective
(Figure 7 A and B). We evaluated Rap-1 activation in response
to some of these pharmacologic treatments. LPS induced Rap1
activation was inhibited in monocytes pretreated with GGTI alone
or with GGTI and p38 MAPK inhibitor, SB203580, but not with
SB203580 alone (Figure 7 C). However, combined use of GGTI-
298 and SB203580 or PD98059 decreased both chemotactic
polarization and migration potential of even the non-LPS treated
cells by ,50%, suggesting that a synergism between MAPK and
Rap1 signaling is required for optimal chemotactic response.
LPS induced rapid global accumulation of PIP3 at the
monocyte plasma membrane
Consistent with the previous reports [18,33], we observed that
LPS treatment increased PIP3 production in monocytes within
3 minutes, which decayed rapidly to basal levels by 5 min (Figure S5
C). In LPS treated cells PIP3 was distributed globally at the plasma
membrane, unlike CCL2 treated cells where PIP3 was localized to
the leading edge in the absence of LPS pretreatment (Figure 2A,
right). LPS pretreatment abolished the F-actin anisotropy in
response to CCL2 (Figure 7 D, right). While PI3K inhibitors
LY2940002 and wortmannin did not significantly alter chemotactic
polarization in untreated cells (Figure 7 D, left), both inhibitors
reversed the LPS induced cell spreading and partially restored
chemotactic polarization in response to CCL2 (Figure 7 D, right).
Discussion
Through multiple criteria, we have shown that LPS and other
TLR2/4 ligands induce a rapid arrest of chemotaxis towards
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e30404Figure 6. Whereas either chemokine or LPS treatment induced Rap-1 activation in monocytes, LPS treatment disrupted the leading
edge localization of activated Rap1 GTPase and Epac-1, the Rap1 GEF. A)1 0
7 monocytes were treated with or without LPS (2 ng/ml) for
15 min followed by 2 min treatment with 20 nM CCL2 or CXCL12. Cytoplasmic extracts were prepared and activated (GTP+) Rap1 was isolated using
a commercial pull-down assay followed by SDS/PAGE and imunoblotting with anti-Rap1 mAb (upper). Cytoplasmic aliquots were analyzed directly for
total cellular Rap1 (lower). B) Rap-1 levels were not significantly altered during a 15 min incubation with increasing amounts (2–100 ng/ml) of LPS.
Cytoplasmic aliquots were analyzed directly for total cellular Rap1. The relative pixel values for Rap1 represent averaged results from using monocyte
from three donors. C) LPS treatment abolished polarization of activated Rap1. Human monocytes on cover slips treated with or without LPS (2 ng/ml)
for 15 min at 37uC were stimulated with 20 nM CCL2 for 2 min. Cells were fixed, permeabilized and incubated with Ral-GDS RBD GST (Thermo
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inducing p38 MAPK activation and preventing polarized
activation Rap1. This effect was obvious within 15 min of LPS
treatment at LPS levels far lower than required for induction of
pro-inflammatory cytokine expression. If monocytes were stimu-
lated with CCL2 or CXCL12 before or simultaneously with LPS,
chemoattractant signaling is predominant. However, given the
protracted nature of TLR signaling and since cells are desensitized
rapidly for chemoattractants, cell spreading and chemotactic arrest
are the eventual outcome with concomitant chemokine and LPS
treatments.
Previous reports have shown that TLR agonists inhibit
monocyte chemotaxis through downregulation or degradation
CCR2 or other CKRs and/or their mRNAs [12,13,14,15,16] or
by endocytic clearance of receptors from the plasma membrane
[17]. Although we observed loss of CCR2 and CXCR4 after
prolonged (.1 h) LPS, under more limited treatment conditions,
there was no reduction in their steady-state levels or G-protein
signaling potential. Furthermore, limited LPS treatment did not
enhance, but induced a modest decrease in the endocytosis of
agonist occupied CKRs.
Chemokines trigger integrin-dependent leukocyte arrest on the
vascular endothelium. Integrin activation harbingers a multi-step
adhesion cascade that orchestrates trans-endothelial migration of
inflammatory cells [34,35]. During trans-endothelial migration
and subsequent chemotaxis through the parenchyma, leukocytes
must execute a delicate balance of adhesion/de-adhesion cycles
[34,35,36,37], which is disrupted during pathogen invasion across
the vascular barrier.
Through inappropriate and persistent integrin activation LPS
induces cell spreading and adhesion, which results in chemotactic
arrest [21]. Monocyte adhesion to HUVECs requires LPS
treatment at 10 ng/ml for at least 30 min [21,38], but this was
insufficient to block chemotaxis during the first 3–10 min. We
have shown that within 2 min of CCL2 or CXCL12 addition,
activated integrins are polarized at the leading edge. While LPS
and other TLR agonists induced substantial global activation of
integrins after 30 min, just 10 min LPS pretreatment was sufficient
to subvert the polarized activation of integrin by chemoattrac-
tant(s).
Inside out signaling through the small GTPase, Rap1 regulates
integrin activation by chemoattractants and other inflammatory
mediators [19,27,39]. Subsequent signals from activated Rap1 are
transduced to RAP1 effector to RapL [40,41], and then to LFA
through SKAP1 [42] and/or Mst1 kinase [43]. In the case of
Rap1 activation by LPS or other extracellular stimuli, the Rap1
signal is transduced through distinct effector(s) like RIAM (Rap1–
GTP-interacting adapter molecule), KRIT-1/CCM (Krev-1/
Rap1 interaction trapped 1/cerebral cavernous malformation)
and AF-6/Cno (ALL1-fused gene from chromosome 6 protein)
proteins, which can assemble adhesion complexes that are
distributed uniformly [28].
Of the five different Rap1 GEFs, we found that Epac1 was
recruited to the leading edge in chemokine treated monocytes.
LPS pretreatment subverted this polarized distribution of Epac1.
In both the social ameba, Dictyostelium and leukocytes many
chemoattractants increase cAMP synthesis through activation of
adenylyl cyclase isoforms II, IV, VII and IX by dissociated Gbc
[44] and as such, cAMP synthesis was relatively enriched at the
leading edge of the polarized leukocyte. We found that LPS
treatment slightly enhanced cAMP synthesis (data not shown),
which may lead to global Epac1 recruitment.
Rap1 independent pathways also activate integrins [32]. For
instance, LPS at 1 mg/ml increased adherence of THP-1
monocytes to immobilized sICAM-1, through PI3K mediated
LFA-1 activation [18]; or through actin reorganization by
activated proline-rich tyrosine kinase 2 (Pyk2) and paxillin [20];
or through a signaling pathway via MyD88, IRAK, p38, and
Rap1 [19]. Consistent with these reports, we found that PI3K
inhibitors reversed LPS induced cell spreading and restored the
chemotactic polarization in response to CCL2.
However, PI3K inhibitors did not block the CCL2 mediated F-
actin polarization in monocytes. Of the multiple isoforms of PI3K,
denoted as Class Ia, Ib, II and III [45], only PI3Kd a Class Ia
member, and PI3Kc, the sole Ib enzyme, have central roles in
leukocyte chemotaxis [46,47,48]. PI3Kc is activated by the Gbc
subunits dissociated from the agonist bound GPCR [45], whereas
Class Ia enzyme(s) are activated by binding to phospho-tyrosine
motifs on receptors utilizing protein tyrosine kinases as their
proximal signal transduction element [49,50] as during TLR
signaling. General PI3K inhibitors, such as wortmannin or
LY294002 may not have knocked out the different PI3K isoforms
equally well. Alternatively, the failure of PI3K inhibitors may
reflect alternative regulation of chemotaxis by PLA2 and PLC
(phospholipase A2 and C) [51,52,53]. PI3K itself is regulated
through PIP2/PTEN by the PLC pathway, while PLA2 depends
on cytosolic Ca
++, which is regulated by IP3 (and thus indirectly by
PLC), fatty acids (and thus partly by PLA2), and Ca
++ uptake.
An intracellular signaling hierarchy regulates neutrophil
migration in opposing gradients of intermediate vs. end-stage
chemoattractants (i.e.CXCL8 vs. fMLF) that use PI3K or p38
MAPK pathways respectively [54,55]. Furthermore, LPS was
shown both in vitro and in vivo to be a p38 MAPK dependent
disrupter of neutrophil migration towards intermediate chemoat-
tractants [11], however the corresponding mechanisms are not as
well defined for monocytes. PI3K/Akt pathway has been reported
to be able to, in turn negatively regulate TLR signaling pathways
at different steps including MAPK cascades (JNK, p38, ERK) and
NF-kB signaling network [56,57].
We confirmed the previous leads showing that LPS induced
modulation of monocyte and neutrophil chemotaxis was depen-
dent on p44/42 ERK and/or p38 MAPK signaling [11,54,58,59],
While small molecular weight inhibitors against MAPKs were
unsuccessful in reversing the LPS effect on monocytes, a partial
reversal of LPS effect was achieved monocytes through the
combined inhibition of Rap1 and p38 MAPK with the caveat that
chemotaxis of untreated cells was also decreased by these agents.
Integrin activation by chemoattractants and other inflammatory
mediators is mediated by inside out signaling through Rap1
[19,27,39]. Polarized Rap1 activation helps reinforce the leading
edge by providing focal nodes for integrin activation and F-actin
attachment. While global Rap1 activation in LPS treated cells
would subvert the nascent leading edge, leading to cell spreading,
inhibiting Rap1 alone may not be sufficient to reverse the LPS
effect through other p38 MAPK targets. Inhibiting both Rap1 and
p38 MAPK would be expected to have a cumulative suppressive
Scientific) for 30 min followed by staining with FITC conjugated anti-GST (BD FACS) and phalloidin-568. D) LPS treatment abolished polarization of
Rap1 GEF, Epac-1. Monocytes on cover slips treated as above were fixed, permeabilized and incubated with anti-Epac-1 followed by staining with
Alexa-488 conjugated anti-rabbit IgG and phalloidin-568. Individual channels corresponding to phalloidin and Rap1 and composite 2-color images
are shown along with DIC images. Data are representative of 3 experiments with human monocytes from 3 different donors.
doi:10.1371/journal.pone.0030404.g006
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and p38 MAPK activation constitute the earliest cellular response
to LPS treatment, inhibiting both of them eliminates LPS effect on
chemotactic polarization.
It was of interest that neutrophil polarization and chemotaxis
were unaffected by TLR ligands under conditions used for
monocytes. However, neutrophils were just as competent as
monocytes in setting up pro-inflammatory cytokine expression
after TLR stimulation. Neutrophils have a short lifespan and are
more proficient sentinels of pathogen invasion than monocytes. It
is therefore reasonable that they have a higher set point for
chemotactic arrest by LPS or other TLR ligands. Although they
Figure 7. Simultaneous inhibition of Rap1 and p38 MAPK or PI3K inhibition reversed LPS induced block of F-actin polarization and
chemotaxis in moncoytes. A) Monocytes in RPMI with 5% FBS were treated with 20 mM Rap1 inhibitor GGTI-298 (Calbiochem, EMD Biosci Corp),
10 mM 42/44ERK MAPK inhibitor PD98059 (Cell signaling), 10 mM p38 MAPK inhibitor SB203580 (Tocris Corp), 20 mM GGTI-298+10 mM PD98059 and
20 mM GGTI-298+10 mM SB203580, or DMSO control for 30 min at 37uC. Cells were plated on cover slips and treated with or without LPS (2 ng/ml) at
37uC for 15 min, followed by stimulation with 20 nM CCL2 for 2 min. Cells were fixed and stained with phalloidin-488, and images were collected
with Leica TCS SP5. B)1 0
7 monocytes were treated with inhibitors as described above for 30 min followed by a 15 min incubation with or without
(control) LPS (2 ng/ml). ,0.5610
6 LPS treated or untreated cells in 100 ml of RPMI with 1% FBS were loaded in the upper Transwell chambers (Nunc
5.0 mm) challenged with or without 20 nM CCL2 in the bottom chambers, and incubated at 37uCC O 2 incubator for 2 h. Chemotaxis was measured as
described under Methods. Migrated cells for control and LPS treatments after respective inhibitors are plotted pair wise in the histograms (with error
bars). n=3,
***p,0.01,
**p,0.04,
*p,0.05. C) LPS induced Rap1 activation was inhibited in monocytes pretreated with GGTI-298 alone or with GGTI-
298 and p38 MAPK inhibitor, SB203580, but not with SB203580 alone. Activated (GTP+) Rap1 was extracted from cytoplasmic extracts using a
commercial pull-down kit followed by SDS/PAGE and imunoblotting with anti-Rap1 mAb. Numbers represent relative fraction (%) of Rapi that was
activated (n=3). D) PI3K inhibitors reversed LPS induced block of F-actin polarization in monocytes stimulated with CCL2. Monocytes in 5%FBS/RPMI
were treated with 50 mM LY2940002, 1 mM wortmannin, or DMSO control for 30 min 37uC. Cells were plated on cover slips and treated with or
without LPS (2 ng/ml) at 37uC for 20 min, followed by 20 nM CCL2 for 2 min. Cells were fixed and stained with phalloidin-488, and images were
collected with Leica TCS SP5.
doi:10.1371/journal.pone.0030404.g007
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with a robust PI3K/PTEN system [60,61,62] that preserves
chemotactic polarization under the more limited LPS treatment
conditions. Neutrophils are also relatively deficient in some key
Rap-1 activators such as Epac1, which is recruited to the plasma
membrane by cAMP [31]; instead they prefer CalDAG GEF,
which is recruited by products of PIP2 hydrolysis by Gbc activated
PLC-b [63]. If and when neutrophils reach the pathogen zone, the
high levels of PAMPs can initiate a robust TLR signaling leading
to chemotactic arrest and formation of neutrophil extracellular
traps (NETs) [64,65].
Blood monocytes are a heterogeneous population and in
humans three different populations have been identified on the
basis of CD14 and CD16 expression [66] and two major human
monocyte subsets, the CD14
+CD16
2 and CD14
loCD16
2 mono-
cytes are defined by CX3CR1 expression [67]. CD14
+CD16
2
monocytes, which constitute about 90% of fresh blood monocytes
were arrested for chemotaxis by LPS treatment. On plating
overnight, CD14
loCD16
2 and CD14
+CD16
+ species emerge,
which preserved LPS induced chemotaxis arrest (not shown) [55].
Monocytes represent a systemic reservoir of relatively immature
myeloid precursors, which differentiate to macrophages DCs
(dendritic cells) and other APCs depending upon the cytokine
environment [68,69,70]. The chemotactic arrest monocytes
experience upon entering the pathogen milieu is consistent with
their rear guard role against pathogen invasion, both by way of
enhanced phagocytosis (Figure S5 C) and antigen processing.
Exposure to low level LPS and other bacterial antigens may
influence monocyte differentiation potential into macrophsges or
DCs and thus modulate the induction of adaptive immune
responses to infection [71]. Stimulating monocytes simultaneously
with multiple TLR ligands as during natural infection may
enhance chemokine secretion, and thus overcome the temporary
inhibition of chemotaxis. By the same token, multiple bacterial
ligands may impose more lasting adhesion and chemotaxis
inhibition. However, the relative magnitudes of these phenotypes
can only be evaluated in sepsis or during massive experimentally
induced peritonitis. Our model is still valid for most natural (pre-
clinical) infections where neutrophils are active patrollers and
monocytes and DCs initiate the transition from innate to acquired
immunity.
Materials and Methods
Cells
Elutriated human monocytes of .98% purity (as judged by
CD14 receptor density) was from the Department of Transfusion
Medicine at the NIH Clinical Center. Human neutrophils were
purified from whole blood as described [72]. HUVECs and U937
cells were purchased from ATCC.
Biochemicals and Reagent Kits
Lipopolysacharide (LPS, from E.coli, serotype O55:B5 or R515
(Re)), lipid A (from E.coli, Serotype R515 (Re)), Macrophage
stimulatory lipopeptide 2 (MALP2), Flagellin, poly (I:C), poly U,
CpG OND, Pam3CSK4, Ac-muramyl-Ala-D-Glu-amide were
purchased from Alexis Biochemicals. Human CCL2, CXCL8,
CXCL12 and fMLF were purchased from Biosource; FURA-2
AM for calcium signaling and phalloidin-568 or phalloidin-488
from Invitrogen. Active Rap1, Rac1, CDC42, pull-down and
detection assay kits and Rap1 assay reagent (Ral GDS-RBD-GST)
were from Piercenet subsidiary of Thermo Scientific; human
cytokine test kits for use in the Luminex plate reader were from
Millipore; p38 kinase inhibitor, SB203580, ERK inhibitor,
PD98059; PI3K inhibitors, LY2940002 and wortmannin; and
Rap-1 specific geranyl-geranyl-transferase inhibitor, GGTI-298
were bought from Calbiochem, EMD Biosciences. 8CPT-2ME-
cAMP was from Tocris Corp.
Antibodies
Unconjugated or Alexa dye conjugated murine mAbs against
phospho-Akt (S473), phospho-p44/42 MAPK (T202/Y204) (clone
E10), phospho-p38 (T180/Y182) (clone 28B10) were from Cell
Signaling; unconjugated or biotinylated anti-PIP3 IgM mAb was
from Echelon Corp. Murine anti-CD11a, anti-CD11b, anti-CD18
(L130) mAbs were from BD scientific; unconjugated or Alexa dye
conjugated antibodies against CD4, CCR2A/2B, CCR3, CCR5,
CCR7, CXCR-1, 2, 3 and 4 were purchased from R&D systems,
MN or BD Biosciences, CA.; murine mAb, CMBR1/5 against
activated Mac-1 was from eBiosciences; N29 and 21C8 mAbs
against activated b1 integrin heterodimers and CBRM1/5 mAb
against activated b2 integrin in Mac-1and rabbit mAbs against
Rap1 and Epac1 were from Abcam. Murine mAb against
activated LFA-1 (mAb24) was kindly provided by Dr. Nancy
Hogg of Cancer Research UK.
TLR Agonist treatments
TLR agonists were used at the following concentration unless
otherwise specified: LPS, 2 ng/ml, Poly (I:C), 20 mg/ml, MALP-2,
200 ng/ml, CpG OND, 2 mg/ml, Pam3CSK4, 50 ng/ml, poly U,
1 mg/ml, flagellin, 200 ng/ml, muramyl-Ala-D-Glu-amide,
100 ng/ml, lipid A, 200 ng/ml. Human primary monocytes or
neutrophils were collected and diluted at 10610
6 cells per ml for
the each respective TLRs agonist stimulation at 37uCi n5 %C O 2
incubator for the indicated duration. In every experiment (unless
specifically indicated otherwise), cells were washed 3X with 5
volumes of RPMI (with 5% FBS) before assays.
Immunoblotting
Treated human monocytes or neutrophils lysed with RIPA
buffer (50 mM HEPES 7.0, 150 mM NaCl, 0.5% Triton X-100,
10% glycerol and protein inhibitor cocktail) at RT for 10 min,
lysates was cleared by at 13,000 rpm spin for 10 min, supernatant
was collected, mixed with 4 X LAD buffer containing 2 mM DTT
(Invitrogen) and boiled for 5 min before SDS/PAGE (4/20%) and
transfer to PVDF or nitrocellulose membranes (Invitrogen) and
immunoblotted with various antibodies followed with HRP
conjugated anti-mouse or anti-rabbit second antibody (Thermo
Scientific). Stained protein bands were developed with Supersignal
west Femto maximum sensitivity substrates (Thermo Scientific)
Flow Cytometry
Cell surface expression of various receptors and intracellular
signaling molecules and F-actin were tested by staining with
fluorescent reagents, and analyzed by flow cytometry as described
extensively before [72]. Monocytes stimulated for 30 min with
100 nM PMA, ionomycin (0.5 mg/ml) or both were used as
positive controls for measuring intracellular kinases and other
signaling molecules. Data were analyzed with program FlowJo
software, version 9.2.
Endocytosis assay
FACS based quantitative analysis of receptor density and
receptor internalization and microscopic visualization of agonist
driven endocytosis have been described [73]. In some experiments
cell surface bound antibody was stripped by treatment for 2 min
with 0.5% acetic acid in 500 mM NaCl.
TLR Signaling on Monocyte Chemotaxis
PLoS ONE | www.plosone.org 12 February 2012 | Volume 7 | Issue 2 | e30404Intracellular (Ca
++) flux
For intracellular Ca
2+ flux in 2610
6 monocytes were loaded
with Fura-2 AM in for 45 min at 37uC HBSS with Ca
2+ and Mg
2+
and containing 1% (w/v) dextrose and 0.5% (w/v) of highly
purified BSA. Cells were washed and resuspended at 1610
6/ml
prior to sequential agonist stimulation in a continuously stirred
cuvette at 37uC in a fluorimeter (Photon Technology Inc., South
Brunswick, NJ as described. Where indicated, cells were treated
with LPS before agonist treatment. Data were recorded every
200 ms as the relative ratio of fluorescence emitted at 510 nm
after sequential excitation at 340 and 380 nm. The integrity of
assay was assessed by comparing the signaling response to
ionomycin treatment before and after each run and the metabolic
integrity of neutrophils was evaluated by comparing the Ca
2+ flux
in response to ATP before and after each run [73].
cAMP assay
Intracellular cAMP levels were assayed using direct cAMP
Enzyme Immunoassay kit (Assay Designs) following manufactur-
er’s instructions. The optical density was read at 405 nm in
FlexStation II microplate scanner and the results were analyzed
using Softmax Pro5 (Molecular Devices,Sunnyvale, CA).
Chemotaxis Assays
End-point chemotaxis was determined using the Trans-well
system with membranes of 6.5 mm diameter and 5.0 m pore size in
RPMI containing 10 mM HEPES and 1% FBS as described [73].
Cells were incubated for 1.5–2 h for neutrophils and 2–2.5 hrs for
monocytes. The ratios of migrated cells were determined from the
number of cells in the lower and upper chambers counted in a cell
sorter after addition of a known number of fluorescent reference
particles (Spherotech, Inc. Libertyville, IL) [72].
Immunofluorescence Microscopy
Cells plated on cover slips after respective treatments were fixed,
permeablized and stained with fluorescent antibodies. Cells were
processed for microscopy as described previously [72]. To 215 -
visualize intracellular lipid and protein mediators of chemotactic
signaling phalloidin-stained cells were reacted with antibodies
against the respective targets [72] in PBS containing saponin
(0.5 mg/ml). Cells were counterstained with dye-conjugated
secondary antibodies as indicated. Cells were visualized by
confocal microscopy as described [74] using a Leica TCS-NT/
SP5 confocal microscope (Leica, Exton, PA USA) equipped with
100X oil immersion objective NA 1.32. Images were processed
using the Leica TCS-NT/SP2 software (version 2.1347) Image-J
(version 1.42l), and Adobe Photoshop CS4.
Supporting Information
Figure S1 Chemotaxis inhibition occurred early after TLR2/4/
6 agonist treatment and was generally irreversible. Monocytes in
triplicate were treated at 37uC with LPS (2 ng/ml) or MALP-2
(200 ng/ml) for 3, 10, 20, 60 and 180 min, washed twice and
allowed to migrate towards 20 nM CCL2 or CXCL12 in a
Transwell chamber. Alternatively, cells were treated with the TLR
agonists for 20 min and then washed and rested for 3, 10, 20, 60
or 120 min (A3–A120) before chemotaxis in Transwell chambers.
Data are plotted as histograms with error bars (n=3).
(TIF)
Figure S2 Cytokine and chemokine secretion profiles of
monocytes treated with selected TLR ligands. Fresh monocytes
were treated with TLR 2 (Pam3CSK4) or TLR4 (LPS) ligands for
the indicated times and cell supernatants were analyzed for
cytokine production using Luminex cytokine profiling assay. A)
Normalized values (in pg/ml) of different cyto/chemokines are
tabulated for each treatment. B) Average cyto/chemokine values
from two experiments for a limited set of TLR ligand treatments
are plotted as histograms.
(TIF)
Figure S3 Short term LPS LPS treatment did not enhance the
magnitude of internalization of agonist occupied CCR2 and
CXCR4, but rather induced a modest inhibition of receptor
clearance at the higher agonist inputs. LPS (2 ng/ml for 15 min at
37uC) treated or untreated monocytes (10
7 cells/ml) were
stimulated with increasing amounts of CCL2 or CXCL12 for
15 min (left), or were stimulated with 100 nM of CCL2 or
CXCL12 for various times (right). Cell surface receptor densities
were evaluated by FACS analysis and data are presented as
percent of MFV values before agonist binding. Data from four
different donors were fit to polynomial regression curves with error
bars. EC50 and t1/2 values for the respective CKR/CK
combinations are denoted by the interpolations on the abscissa.
(TIF)
Figure S4 A) Selected antibodies against quiescent or activated
heterodimers inhibit relative chemotaxis of monocytes towards
CCL2, CXCL12 or fMLF. after preincubation with the indicated
antibodies. Fresh monocytes (10
7/ml) in RPMI (5% FCS) medium
pre-treated for 15 min with the indicated antibodies or IgG
control prior to chemotaxis assay in Transwell chambers against
the indicated agonists. Fraction of migrated cells for each
condition is pltted in the histogram (with error bars, n=4). B)
Time course of ß-2 integrin activation by TLR agonists. Fresh
monocytes (10
7/ml) in RPMI (5% FCS) were treated with the
indicated TLR or NOD2 ligands and 100 ml samples were
collected after 0,15, 30, 60, 100, 180 min or overnight (16 hrs)
treatment and stained with APC conjugated MEM148 mAb
targeted against the ß-2 integrin activation epitope at 4uC for
30 min, and analyzed by flow cytometry. MFVs relative to
untreated cells are plotted as histograms (with error bars) (n=3).
C) Time course of monocyte adhesion after LPS stimulation,
HUVEC (ATCC, PCS-100-030, second passage) cells were
incubated in sterile Greiner black transparent 96-well plates at
density of 30000 cells/well one day before the assay. Monocytes
treated with DMSO or LPS (2 ng/ml) for 3, 10, 60 or 120 min
were washed 3 X and resuspended at 5610
6 cells/ml in RPMI
without serum and containing 2.5 mM calcein AM at 37uC for
30 min. Cells were washed thrice and resuspended in RPMI at
2.5610
6 cells/ml and 100 ml of calcein-labeled cells were layered
on HUVEC cells in 96-well plates and incubated for 30 min..
Non-adherent cells were removed by 5 X washes and calcein
fluorescence was measured by Flexstation at Ex494/Em517. Cell
adhesion (%) was determined from the fraction of bound to total
fluorescence. Alternatively, monocytes were rested for 3 (A3), 10
(A10) or 120 min (A120) in normal medium after 30 min pre-
treatment DMSO (clear bars) or LPS (2 ng/ml) (black bars),
before loading and HUVEC adhesion. Histograms are represen-
tative of two experiments.
(TIF)
Figure S5 A) LPS pretreatment abolished polarized Rap1
accumulation in monocytes following chemokine stimulation.
Monocytes (10
6) on cover slips were treated with or without LPS
(2 ng/ml) for 15 min at 37uC and then stimulated with 20 nM
CCL2 or CXCL12 for 2 min. Cells were fixed, permeabilized and
incubated with rabbit anti-Rap1 antibody followed by Alexa488-
anti-Rabbit IgG. Individual channels corresponding to phalloidin
TLR Signaling on Monocyte Chemotaxis
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DIC images. Data are representative of 3 experiments with human
monocytes from 3 different donors. B) Epac-1 activation by
8CPT-2Me-cAMP induced cell-spreading resembling that induced
by LPS treatment. Monocytes (0.5610
6) were treated with DMSO
or LPS (2 ng/ml) at 37 degrees for 15 min or 8CPT-2Me-cAMP
(400 mM) for 40 min in 100 ml of RPMI containing 1% FBS. Cells
were fixed and stained with Alexa-568 conjugated phalloidin and
examined by fluorescent microscopy. Photomicrograph is repre-
sentative of three independent experiments using cells from three
donors. C) LPS treatment induced rapid PIP3 accumulation,
which decayed just as quickly. Monocytes (,10
6 cells), treated
with or without LPS (2 ng/ml) for 1, 2, 3, 4, 5 or 30 min were
collected, fixed, and permeabilized with 0.2% saponin for 10 min
at 4uC, incubated with mouse anti-PIP3 IgM (Echelon) followed by
staining with Alexa-488 anti-mouse IgM for 30 min and analyzed
by flow cytometry. Histogram (with error bars) shows PIP3 MFVs
averaged from three experiments (n=3).
(TIF)
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